Quick Answer
Dogwood Therapeutics, Inc. reported Cash and Equivalents of $6.52 million for fiscal year 2025.
Dogwood Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.52M | -56.1% |
| 2024 | $14.85M | +347.6% |
| 2023 | $3.32M | -52.8% |
| 2022 | $7.03M | -49.8% |
| 2021 | $14.01M | -53.0% |
| 2020 | $29.80M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.13M | +396.5% | -24.4% |
| June 30, 2025 | $13.40M | +343.8% | -23.6% |
| March 31, 2025 | $17.54M | +637.1% | +18.1% |
| December 31, 2024 | $14.85M | +347.6% | +627.9% |
| September 30, 2024 | $2.04M | -57.4% | -32.5% |
| June 30, 2024 | $3.02M | -34.2% | +26.9% |
| March 31, 2024 | $2.38M | -55.4% | -28.3% |
| December 31, 2023 | $3.32M | -52.8% | -30.7% |
- Dogwood Therapeutics, Inc. showed a decrease of -56.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Dogwood Therapeutics, Inc.’s cash and equivalents has declined by 78.1% (from $29.80 million to $6.52 million).
- The most recent figure is from Dogwood Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: